

AREA PRESCRIBING COMMITTEE – ACTION LIST 11th JUNE 2015

Action Reference	Minute Reference	ACTION	OWNER	FURTHER COMMENTS	TARGET DATE	STATUS (R/A/Clear)
14/026	69/14	DMARDS Monitoring - Methotrexate	BG/TS	On Agenda	30.04.2015	ONGOING
14/027	70/14	DOMPERIDONE FOR CHILDREN Manchester Paediatric Consultant now drafting guideline for approval.	PB	No timescale at present.	30.04.2015	AMBER ONGOING
14/036	85/14	PRIMARY CARE MANAGEMENT OF CELLULITIS AL to share presentation to members.	AL	AL to attend second meeting in July 2015.	30.04.2015	AMBER ONGOING
14/041	107/14 & 19/15	Comments on DRAFT PPIs ALGORITHM PB to feedback the APC comments.	All	Comments to go back to PB. Concern over prescribing of Gaviscon Advance or Peptac. Prescribing of Alginate instead of a brand.	30.04.2015	AMBER ONGOING
14/044	111/14	Proposal for the use of NOACs for cardioversion required from Dr Brodison	PB	Approved by N. Lancs APC, PB to forward N.Lancs APC papers to the group.	30.04.2015	AMBER ONGOING
14/045	114/14	Bring proposal for dementia patients reviews as part of the SCG	HH	Darren Reynolds will attend the next meeting, has been given the date for August APC.	30.04.2015	AMBER ONGOING
14/050	134/14	Draft a formal statement about the second line use of anti-TNFs for psoriatic arthritis in line with the decisions of the IFR panel.	AL TS	Statement to be passed to Rheumatologists as part of Blueteq. TS to change wording slightly.	30.04.2015	RED
ACTIONS FOR 2015						
15/07	15/15	Nabilone Red drug at present. PB would like it to be black.	TS	Status to be reviewed for newly prescribed patients. PB to write a paper as to reasons for changing to Black.	30.04.2015	ONGOING
15/08	16/15	Branded generics AL to speak to TS about rewording the paper.	AL TS	The APC supported the paper in principle but requested rewording the statement to stress generic prescribing with specified exemptions. Statement to be brought to the August meeting.	12.08.2015	ONGOING

15/09	20/15	<p>Sick Day Medication PB to work on Acute kidney injury in UHMBT and to circulate the national document through the APC Awaiting the national circulation</p>	PB	<p>AQA Document is thought to be too detailed and is not being used by UHMBT. Waiting for new national document to be published.</p>	11.06.2015	AMBER ONGOING
15/12		<p>Mycophenolate mofetil – PB will check the current version of shared care protocol. AL to check for North Cumbria.</p>	PB AL	<p>Amendment to be made to SC guideline for UHMBT. Noted that blood test are to be done by primary care.</p>	11.06.2015	AMBER ONGOING
15/15	69/14	<p>DMARDS Monitoring PB to meet next month with Rheumatology consultants and to liaise with BG with a view to adopt the North Lancashire Shared Care Guidelines.</p>	PB BG	<p>BG to take approved SCG to NCUHT.</p>	11.06.2015	
15/16	33/15	<p>NICE CG Medicines Optimisation AL to share slides with the group and report on the current position in relation to the medicines optimization.</p>	AL	<p>Base line assessment to be completed at next APC.</p>	11.06.2015	ONGOING
15/17	34/15	<p>Contract Monitoring BG & TS to meet to complete the set up of Dermatology and Blueteq.</p>	BG		11.06.2015	ONGOING
15/18	38/15	<p>PDE-5 INHIBITORS FOR ERECTILE DYSFUNCTION Generic prescribing of Sildenafil only unless they meet the SLS criteria. LA to amend the Supporting Section of the document and take off the last sentence then issue.</p>	LA		11.06.2015	
15/19	52/15	<p>Topical Ketoprofen ScriptSwitch message to be added to advise prescribers not to prescribe.</p>	LA	<p>LA to contact PC.</p>	12.08.2015	

15/20	54/15	<p>NTAG-Rituximab for Immune Thrombocytopenic Purpura</p> <p>This drug has been approved North of Tyne but not agreed in Northumberland.</p> <p>Drug to be added to Bluteq.</p> <p>AL to check if the Drug is CCG Commissioned</p>	TS AL		12.08.2015	ONGOING
15/21	56/15	<p>Pentosan Polysulfate – RAG Classification</p> <p>Black</p>	TS		12.08.2015	
15/22	57/15	<p>Prescribing of Sevelamer & Lanthanum, Primary or Secondary Care?</p> <p>AL to feedback at next meeting with regards to shared care?</p> <p>BG to provide AL with financial impact report?</p>	AL BG		12.08.2015	ONGOING
15/23	61/15	<p>Infliximab Biosimilars</p> <p>PB is to meet with UHMBT Consultants July 15, papers will then be circulated to members. To be discussed at next meeting.</p>	PB		12.08.2015	ONGOING
15/24	62/15	<p>Supply of IV Antibiotics in the community</p> <p>Agreed that pathways for administration of IV antibiotics in the community need to be developed although unclear which organisation is the lead provider. Mainly prescribed by the NCUHT and administered by CPFT community nursing teams.</p>	BG	BG to raise the question in his organisation.	12.08.2015	ONGOING
15/25	66/15	<p>Drug Safety Update</p> <p>April – Prescription Pad & PMM’s updated with information regarding Hydroxyzine and Codeine.</p> <p>Insulin degludec – not approved by LJF on the basis of non-submission by the company. BG had</p>	TS		12.08.2015	

	<p>received requests for two patients which have been rejected.. However, it was reported that CPFT Cumbria Diabetes Service does prescribe insulin degludec. Updated NICE diabetes guidelines are due later this year. NICE evidence summary states that insulin degludec is comparable to insulin glargine. BG to request clinicians prepare a formulary application.</p>	<p>BG</p>			
--	---	-----------	--	--	--